FAIL (the browser should render some flash content, not this).
homeservicesproductstechnologiesreferencescontactus


FAQs

Q. What is the required biosafety level for handling recombinant adenovirus?

A. Our recombinant adenoviruses that are deleted in the E1 and E3 regions will replicate in HEK293 cells, but not in other cell lines. According to the NIH Office of Biosafety, recombinant human adenovirus has been classified in biosafety level II for agents considered of ordinary potential harm, and you need BL-2 level facility to work with it. It should be noted that cell culture facilities in most institutes are certified as BL-2 level.
For more information on biosafety levels, please refer to the following CDC publication: Biosafety in Microbiological and Biomedical Laboratories, 4th Edition, May 1999; this publication is also available at http://bmbl.od.nih.gov.

Q. What type of cells are used to produce and grow recombinant Adenoviruses in your systems?

A. Human Embryonic Kidney cell line, the HEK-293 cells. The 293 cells contain the full E1 region of the Adenovirus type 5, from nucleotides 1 to 4355 of Ad5 wt, making these cells suitable for the generation and growth of helper-independent recombinant Adenoviruses.

Q. How are recombinant adenoviruses purified and virus titers determined?

A. The amplified recombinant adenovirus was purified on 2 sequential cesium chloride gradients and then dialyzed with a buffer (PBS, 10% glycerol, pH7.4) to reduce the salt concentration. The titer of purified virus can be determined with (1) OD260 Assay or (2) Plaque Assay.

The OD260 assay measures the concentration of viral DNA and protein. It does not distinguish between intact, infectious viruses and damaged, non-infectious viruses. It is a physical assay measuring the concentration of total viruses, live and dead. Based on OD260 data, the concentration of viral particles (VP) can be calculated using the following formula:

Adenovirus titer in viral particles/ml = OD value x d x 1.1 x 1012; ( d= dilution factor)

The plaque assay measures the concentration of infectious viruses, and therefore it is a biological assay. Basically, a mono-layer of HEK293 cells are infected with a series of virus dilutions. Viruses will propagate in infected cells, and eventually leading to the formation of holes or plaques. Thus, a PFU can be determined from a plaque assay.

Q. What are the differences between viral particle (VP) and plaque formation unit (PFU)?

A. Viral particles (VPs) represent the total number of viral particles (live and dead combined). Because of variations in viral preparations the ratio of live/dead varies significantly. Thus, VP doesn’t reflect the amount of live virus in the preparation.

PFU (plaque formation unit) represents the number of infectious or live viruses. It reflects the amount of working viruses in the preparation.

For most virus preps, the VP/PFU ratio is 20:1 to 50:1.

Q. What are the conditions recommended for the storage of recombinant adenovirus preparations?

A. For long-term storage, the virus should be stored at -80°C, especially after CsCl purification. At -80°C, the virus could be stable for at least a year. However, the repeated freeze-and-thaw should be avoided, since it will cause significant decrease of titer.

Q. What size of insert can be cloned into the Adenoviral expression system?

A. The insert size limitation for the DE1/E3 deleted Ad5 vector is about 8 Kb in length.

Q. What are RCAs?

A. The replication competent adenoviruses (RCAs) is a result of the rare double crossover through overlapping sequences present in the recombinant adenovirus and the genome of HEK293 cells. This event results in the replacement of the transgene by E1 region. Once this happens, the adenovirus could replicate, without the need of a complementing cell line. Usually two methods, non-complementary A549 cells or PCR could be used to detect RCA in a recombinant adenoviral preparation.

According to NIH guideline, <1 plaque in about 1E4 viruses is considered safe to use. To avoid the occurrence of RCA, viruses should be produced and amplified in low passage packaging cells.

Q. What MOI (multiplicity of infection) should I use with my cells?

A. Usually, a MOI of 1 is suitable to infect 293 cells. If you use other cell lines and the susceptibility to Adenovirus infection is unknown, you should test a MOI (number of virus per cell) range between 1 and 1000. The MOI may be increased up to 10000 when testing a mouse cell line. For most cell lines, the transfer of a reporter gene (for example, GFP) to 100% of cells, without any signs of toxicity, can be achieved with a MOI of 10-100.

Q. Which viral expression system (adenovirus, retrovirus and lentivirus) should I use for my experiments?

A. Adenovirus can infect many types of mammalian including dividing and non-dividing or primary cells with high efficiency. They do not disrupt the genome of the host cell but remain in the nucleus as episomal DNA. However, adenovirus only provides a transient, high level gene expression in vitro and in vivo.

Retrovirus has low infection efficiency (<30%) in most cell types, and requires active cell division. In addition, there is a significant risk of integration into the host genome, leading to mutation of genes or activation of onco-genes in the host system. Unlike adenovirus, the costs of production of recombinant retrovirus are very expensive, which may limit your in vivo application.

Like Retrovirus, Lentivirus has low infection efficiency (<30%) in both dividing and non-dividing cells. Lentivirus also can integrate into the host genome, leading to mutation of genes or activation of oncogenes in the host system. As with retrovirus, the costs of production of recombinant retrovirus are very expensive.


back to top


WHAT IS NEW
DNA that encodes a small hairpin RNA (shRNA) molecule will be inserted into the adenoviral genome, in which the expression of shRNA is under the control of the U6 or CMV promoter.

  • Custom AAV Service
  • RNAi Service

FAQS
Welgen technical specialists are professional researchers with laboratory and product experience. Feel free to contact us with your technical or product inquiry.

read more

TECH RESOURCES
Adenovirus and RNAi Services performed by Welgen Inc. have been referenced by the publications:
.Sheng G et al. 2006. Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nature Medcine. 12:526-33
read more












100 Barber Avenue, Worcester, MA 01606 || info@welgeninc.com || 888-493-5436 or 508-791-9966 phone || 508-791-9948 fax
Copyright © 2008 Welgen, Inc.       Website designed by YY Graphic Design